LATUDA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Estonia, Finland, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug LATUDA contains one active pharmaceutical ingredient (API):

1	Lurasidone UNII O0P4I5851I - LURASIDONE HYDROCHLORIDE
	Lurasidone is a selective blocking agent of dopamine and monoamine effects indicated for the treatment of schizophrenia. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7 receptors. Lurasidone does not bind to histaminergic or muscarinic receptors.
	Read more about Lurasidone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LATUDA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AE05		N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AE Indole derivatives
Discover more medicines within N05AE05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10526B, 10529E
BR	Câmara de Regulação do Mercado de Medicamentos	530418030014102, 530418030014202, 530418030014302, 530418030014402, 530418030014502, 530418030014602, 530418030014702, 530418030014802, 530418030014902, 530418030015002, 530418030015102, 530418030015202
CA	Health Products and Food Branch	02387751, 02387778, 02387786, 02413361, 02422050
EE	Ravimiamet	1644162, 1644173, 1644184, 1644195, 1644207, 1644218, 1644229, 1644230, 1644241, 1644252, 1644263, 1644274, 1644285, 1644296, 1644308, 1644319, 1644320, 1644331, 1644342, 1644353, 1644364, 1849574
ES	Centro de información online de medicamentos de la AEMPS	114913002, 114913009, 114913016
FI	Lääkealan turvallisuus- ja kehittämiskeskus	053309, 092535, 410432, 486157, 538197
GB	Medicines & Healthcare Products Regulatory Agency	266545, 266548, 266551, 368132, 375159, 375161, 375163, 376729, 381456, 381458, 381460
HK	Department of Health Drug Office	64804, 64806, 67186
IT	Agenzia del Farmaco	043335013, 043335025, 043335037, 043335049, 043335052, 043335064, 043335076, 043335088, 043335090, 043335102, 043335114, 043335126, 043335138, 043335140, 043335153, 043335165, 043335177, 043335189, 043335191, 043335203, 043335215
JP	医薬品医療機器総合機構	1179061F1022, 1179061F2029, 1179061F3025, 1179061F4021
LT	Valstybinė vaistų kontrolės tarnyba	1073059, 1073061, 1073062, 1073063, 1073064, 1073065, 1073066, 1073067, 1073068, 1073069, 1073070, 1073071, 1073072, 1073073, 1073074, 1073075, 1073076, 1073077, 1073078, 1073079, 1073080
NL	Z-Index G-Standaard, PRK	118524, 118532, 132683
PL	Rejestru Produktów Leczniczych	100209033, 100302896, 100314379
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64570001, W64570002, W64570003, W64570004, W64570005, W64570006, W64570007, W64571001, W64571002, W64571003, W64571004, W64571005, W64571006, W64571007, W64572001, W64572002, W64572003, W64572004, W64572005, W64572006, W64572007
SG	Health Sciences Authority	15088P, 15089P
US	FDA, National Drug Code	63402-302, 63402-304, 63402-306, 63402-308, 63402-312, 70518-1812, 70518-1824